Aligos Therapeutics stops development of CHB drug candidate ALG-010133
Aligos Therapeutics has stopped further development of ALG-010133, its STOPS drug candidate, in chronic hepatitis B (CHB) owing to futility. The California-based clinical stage biopharma ... Read More